Global Drugs based on Genetic Engineering Market Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08253530

Publication Date:

August 6, 2025

Pages:

135

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Drugs based on Genetic Engineering market size will reach US$ 483902 million by 2031.
Drugs based on genetic engineering are pharmaceutical products developed using biotechnology techniques such as recombinant DNA technology, gene editing, or synthetic biology. These drugs are typically proteins, peptides, nucleic acids, or living cells that are designed to prevent, treat, or cure diseases by modifying or influencing genetic or molecular pathways in the body.
United States market for Drugs based on Genetic Engineering is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Drugs based on Genetic Engineering is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Drugs based on Genetic Engineering is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Drugs based on Genetic Engineering players cover Novo Nordisk, Amgen, Eli Lilly, Sanofi, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒rugs based on Genetic Engineering Industry Forecast鈥� looks at past sales and reviews total world Drugs based on Genetic Engineering sales in 2024, providing a comprehensive analysis by region and market sector of projected Drugs based on Genetic Engineering sales for 2025 through 2031. With Drugs based on Genetic Engineering sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs based on Genetic Engineering industry.
This Insight Report provides a comprehensive analysis of the global Drugs based on Genetic Engineering landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drugs based on Genetic Engineering portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Drugs based on Genetic Engineering market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs based on Genetic Engineering and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs based on Genetic Engineering.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs based on Genetic Engineering market by product type, application, key players and key regions and countries.
Segmentation by Type:
Fusion Protein
Recombinant Growth Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Recombinant Coagulation Factor
Other
Segmentation by Application:
Cancers
Autoimmune Diseases
Metabolic Disorders
Infectious Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Amgen
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
AbbVie
Sandoz
Biogen
Pfizer
GenSci
3SBIO
Organon Pharma
Roche
Swedish Orphan Biovitrum
CSPC
Johnson & Johnson
Merck
Takeda

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs based on Genetic Engineering Market Size (2020-2031)
2.1.2 Drugs based on Genetic Engineering Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Drugs based on Genetic Engineering by Country/Region (2020, 2024 & 2031)
2.2 Drugs based on Genetic Engineering Segment by Type
2.2.1 Fusion Protein
2.2.2 Recombinant Growth Factor
2.2.3 Recombinant Hormone
2.2.4 Recombinant Interferon
2.2.5 Recombinant Interleukin
2.2.6 Recombinant Coagulation Factor
2.2.7 Other
2.3 Drugs based on Genetic Engineering Market Size by Type
2.3.1 Drugs based on Genetic Engineering Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Drugs based on Genetic Engineering Market Size Market Share by Type (2020-2025)
2.4 Drugs based on Genetic Engineering Segment by Application
2.4.1 Cancers
2.4.2 Autoimmune Diseases
2.4.3 Metabolic Disorders
2.4.4 Infectious Diseases
2.5 Drugs based on Genetic Engineering Market Size by Application
2.5.1 Drugs based on Genetic Engineering Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Drugs based on Genetic Engineering Market Size Market Share by Application (2020-2025)
3 Drugs based on Genetic Engineering Market Size by Player
3.1 Drugs based on Genetic Engineering Market Size Market Share by Player
3.1.1 Global Drugs based on Genetic Engineering Revenue by Player (2020-2025)
3.1.2 Global Drugs based on Genetic Engineering Revenue Market Share by Player (2020-2025)
3.2 Global Drugs based on Genetic Engineering Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drugs based on Genetic Engineering by Region
4.1 Drugs based on Genetic Engineering Market Size by Region (2020-2025)
4.2 Global Drugs based on Genetic Engineering Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drugs based on Genetic Engineering Market Size Growth (2020-2025)
4.4 APAC Drugs based on Genetic Engineering Market Size Growth (2020-2025)
4.5 Europe Drugs based on Genetic Engineering Market Size Growth (2020-2025)
4.6 Middle East & Africa Drugs based on Genetic Engineering Market Size Growth (2020-2025)
5 Americas
5.1 Americas Drugs based on Genetic Engineering Market Size by Country (2020-2025)
5.2 Americas Drugs based on Genetic Engineering Market Size by Type (2020-2025)
5.3 Americas Drugs based on Genetic Engineering Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs based on Genetic Engineering Market Size by Region (2020-2025)
6.2 APAC Drugs based on Genetic Engineering Market Size by Type (2020-2025)
6.3 APAC Drugs based on Genetic Engineering Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drugs based on Genetic Engineering Market Size by Country (2020-2025)
7.2 Europe Drugs based on Genetic Engineering Market Size by Type (2020-2025)
7.3 Europe Drugs based on Genetic Engineering Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drugs based on Genetic Engineering by Region (2020-2025)
8.2 Middle East & Africa Drugs based on Genetic Engineering Market Size by Type (2020-2025)
8.3 Middle East & Africa Drugs based on Genetic Engineering Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Drugs based on Genetic Engineering Market Forecast
10.1 Global Drugs based on Genetic Engineering Forecast by Region (2026-2031)
10.1.1 Global Drugs based on Genetic Engineering Forecast by Region (2026-2031)
10.1.2 Americas Drugs based on Genetic Engineering Forecast
10.1.3 APAC Drugs based on Genetic Engineering Forecast
10.1.4 Europe Drugs based on Genetic Engineering Forecast
10.1.5 Middle East & Africa Drugs based on Genetic Engineering Forecast
10.2 Americas Drugs based on Genetic Engineering Forecast by Country (2026-2031)
10.2.1 United States Market Drugs based on Genetic Engineering Forecast
10.2.2 Canada Market Drugs based on Genetic Engineering Forecast
10.2.3 Mexico Market Drugs based on Genetic Engineering Forecast
10.2.4 Brazil Market Drugs based on Genetic Engineering Forecast
10.3 APAC Drugs based on Genetic Engineering Forecast by Region (2026-2031)
10.3.1 China Drugs based on Genetic Engineering Market Forecast
10.3.2 Japan Market Drugs based on Genetic Engineering Forecast
10.3.3 Korea Market Drugs based on Genetic Engineering Forecast
10.3.4 Southeast Asia Market Drugs based on Genetic Engineering Forecast
10.3.5 India Market Drugs based on Genetic Engineering Forecast
10.3.6 Australia Market Drugs based on Genetic Engineering Forecast
10.4 Europe Drugs based on Genetic Engineering Forecast by Country (2026-2031)
10.4.1 Germany Market Drugs based on Genetic Engineering Forecast
10.4.2 France Market Drugs based on Genetic Engineering Forecast
10.4.3 UK Market Drugs based on Genetic Engineering Forecast
10.4.4 Italy Market Drugs based on Genetic Engineering Forecast
10.4.5 Russia Market Drugs based on Genetic Engineering Forecast
10.5 Middle East & Africa Drugs based on Genetic Engineering Forecast by Region (2026-2031)
10.5.1 Egypt Market Drugs based on Genetic Engineering Forecast
10.5.2 South Africa Market Drugs based on Genetic Engineering Forecast
10.5.3 Israel Market Drugs based on Genetic Engineering Forecast
10.5.4 Turkey Market Drugs based on Genetic Engineering Forecast
10.6 Global Drugs based on Genetic Engineering Forecast by Type (2026-2031)
10.7 Global Drugs based on Genetic Engineering Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Drugs based on Genetic Engineering Forecast
11 Key Players Analysis
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Drugs based on Genetic Engineering Product Offered
11.1.3 Novo Nordisk Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Drugs based on Genetic Engineering Product Offered
11.2.3 Amgen Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly Drugs based on Genetic Engineering Product Offered
11.3.3 Eli Lilly Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Drugs based on Genetic Engineering Product Offered
11.4.3 Sanofi Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Drugs based on Genetic Engineering Product Offered
11.5.3 Bayer Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Bayer Main Business Overview
11.5.5 Bayer Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Drugs based on Genetic Engineering Product Offered
11.6.3 Bristol-Myers Squibb Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Information
11.7.2 GlaxoSmithKline Drugs based on Genetic Engineering Product Offered
11.7.3 GlaxoSmithKline Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 GlaxoSmithKline Main Business Overview
11.7.5 GlaxoSmithKline Latest Developments
11.8 AbbVie
11.8.1 AbbVie Company Information
11.8.2 AbbVie Drugs based on Genetic Engineering Product Offered
11.8.3 AbbVie Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 AbbVie Main Business Overview
11.8.5 AbbVie Latest Developments
11.9 Sandoz
11.9.1 Sandoz Company Information
11.9.2 Sandoz Drugs based on Genetic Engineering Product Offered
11.9.3 Sandoz Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Sandoz Main Business Overview
11.9.5 Sandoz Latest Developments
11.10 Biogen
11.10.1 Biogen Company Information
11.10.2 Biogen Drugs based on Genetic Engineering Product Offered
11.10.3 Biogen Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Biogen Main Business Overview
11.10.5 Biogen Latest Developments
11.11 Pfizer
11.11.1 Pfizer Company Information
11.11.2 Pfizer Drugs based on Genetic Engineering Product Offered
11.11.3 Pfizer Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Pfizer Main Business Overview
11.11.5 Pfizer Latest Developments
11.12 GenSci
11.12.1 GenSci Company Information
11.12.2 GenSci Drugs based on Genetic Engineering Product Offered
11.12.3 GenSci Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 GenSci Main Business Overview
11.12.5 GenSci Latest Developments
11.13 3SBIO
11.13.1 3SBIO Company Information
11.13.2 3SBIO Drugs based on Genetic Engineering Product Offered
11.13.3 3SBIO Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 3SBIO Main Business Overview
11.13.5 3SBIO Latest Developments
11.14 Organon Pharma
11.14.1 Organon Pharma Company Information
11.14.2 Organon Pharma Drugs based on Genetic Engineering Product Offered
11.14.3 Organon Pharma Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Organon Pharma Main Business Overview
11.14.5 Organon Pharma Latest Developments
11.15 Roche
11.15.1 Roche Company Information
11.15.2 Roche Drugs based on Genetic Engineering Product Offered
11.15.3 Roche Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Roche Main Business Overview
11.15.5 Roche Latest Developments
11.16 Swedish Orphan Biovitrum
11.16.1 Swedish Orphan Biovitrum Company Information
11.16.2 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Product Offered
11.16.3 Swedish Orphan Biovitrum Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Swedish Orphan Biovitrum Main Business Overview
11.16.5 Swedish Orphan Biovitrum Latest Developments
11.17 CSPC
11.17.1 CSPC Company Information
11.17.2 CSPC Drugs based on Genetic Engineering Product Offered
11.17.3 CSPC Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 CSPC Main Business Overview
11.17.5 CSPC Latest Developments
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Information
11.18.2 Johnson & Johnson Drugs based on Genetic Engineering Product Offered
11.18.3 Johnson & Johnson Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Johnson & Johnson Main Business Overview
11.18.5 Johnson & Johnson Latest Developments
11.19 Merck
11.19.1 Merck Company Information
11.19.2 Merck Drugs based on Genetic Engineering Product Offered
11.19.3 Merck Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Merck Main Business Overview
11.19.5 Merck Latest Developments
11.20 Takeda
11.20.1 Takeda Company Information
11.20.2 Takeda Drugs based on Genetic Engineering Product Offered
11.20.3 Takeda Drugs based on Genetic Engineering Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Takeda Main Business Overview
11.20.5 Takeda Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂